{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:41:17Z","timestamp":1791351677223,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000774","name":"University of Newcastle","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s41669-025-00606-x","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:48:56Z","timestamp":1761241736000},"page":"97-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0221-8404","authenticated-orcid":false,"given":"Xiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6818-6636","authenticated-orcid":false,"given":"David","family":"Newby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3329-3095","authenticated-orcid":false,"given":"Shuchuen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"606_CR1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","author":"S Klineova","year":"2018","unstructured":"Klineova S, Lublin FD. Clinical course of multiple sclerosis. Cold Spring Harb Perspect Med. 2018. https:\/\/doi.org\/10.1101\/cshperspect.a028928.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"606_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, et al. ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler J. 2018;24:96\u2013120.","journal-title":"Mult Scler J"},{"key":"606_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1017\/S0317167100014244","volume":"40","author":"MS Freedman","year":"2013","unstructured":"Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M, et al. Treatment optimization in MS: Canadian MS working group updated recommendations. Can J Neurol Sci. 2013;40:307\u201323.","journal-title":"Can J Neurol Sci"},{"key":"606_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.08.016","volume":"36","author":"SB Claflin","year":"2019","unstructured":"Claflin SB, Tan B, Taylor BV. The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord. 2019;36:101374.","journal-title":"Mult Scler Relat Disord"},{"key":"606_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/13696998.2016.1258366","volume":"20","author":"D Bozkaya","year":"2017","unstructured":"Bozkaya D, Livingston T, Migliaccio-Walle K, Odom T. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2017;20:297\u2013302.","journal-title":"J Med Econ"},{"key":"606_CR6","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13180.1","volume":"6","author":"S Tantivess","year":"2017","unstructured":"Tantivess S, Chalkidou K, Tritasavit N, Teerawattananon Y. Health technology assessment capacity development in low-and middle-income countries: experiences from the international units of HITAP and NICE. F1000Res. 2017;6:2119.","journal-title":"F1000Res"},{"key":"606_CR7","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jval.2021.11.1356","volume":"25","author":"MA Hogervorst","year":"2022","unstructured":"Hogervorst MA, Vreman RA, Mantel-Teeuwisse AK, Goettsch WG. Reported challenges in health technology assessment of complex health technologies. Value Health. 2022;25:992\u20131001.","journal-title":"Value Health"},{"key":"606_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00384","volume":"8","author":"N Allen","year":"2017","unstructured":"Allen N, Liberti L, Walker SR, Salek S. A comparison of reimbursement recommendations by European HTA agencies: is there opportunity for further alignment? Front Pharmacol. 2017;8:384.","journal-title":"Front Pharmacol"},{"key":"606_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jval.2016.10.014","volume":"20","author":"N Allen","year":"2017","unstructured":"Allen N, Walker SR, Liberti L, Salek S. Health technology assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England, and Scotland. Value Health. 2017;20:320\u20138. https:\/\/doi.org\/10.1016\/j.jval.2016.10.014.","journal-title":"Value Health"},{"key":"606_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2022.970661","volume":"2","author":"L Gozzo","year":"2022","unstructured":"Gozzo L, Paterson K, Wong O, Megerlin F, Geldmacher J, Popoli P, et al. Towards a European harmonization of health technology assessment recommendations executive paper of European regulatory conference focused on the EU commission proposal to harmonize HTA. Front Drug Saf Regul. 2022;2:970661.","journal-title":"Front Drug Saf Regul"},{"key":"606_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.754482","volume":"9","author":"T Qiu","year":"2021","unstructured":"Qiu T, Liang S, Wang Y, Dussart C, Borissov B, Toumi M. Reinforcing collaboration and harmonization to unlock the potentials of advanced therapy medical products: future efforts are awaited from manufacturers and decision-makers. Front Public Health. 2021;9:754482.","journal-title":"Front Public Health"},{"key":"606_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.1503","volume":"25","author":"S Gillard","year":"2022","unstructured":"Gillard S, Ioannou P, Bashford-Bovens S. HTA43 multi-country HTA initiatives versus national HTA processes: the optimal reimbursement strategy. Value Health. 2022;25:S304.","journal-title":"Value Health"},{"key":"606_CR13","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232200037X","author":"I Imaz-Iglesia","year":"2022","unstructured":"Imaz-Iglesia I, Wild C. EUnetHTA\u2019s contribution to the new legal framework for health technology assessment cooperation in Europe. Int J Technol Assess Health Care. 2022. https:\/\/doi.org\/10.1017\/S026646232200037X.","journal-title":"Int J Technol Assess Health Care"},{"key":"606_CR14","unstructured":"Union E. Regulation (EU) 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011\/24\/EU. In Book Regulation (EU) 2021\/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment and amending Directive 2011\/24\/EU (Editor ed.^eds.). City; 2021."},{"key":"606_CR15","unstructured":"Health CAfDaTi. CADTH Partners With International Health Technology Assessment Bodies to Boost Collaboration on Shared Challenges. https:\/\/www.cadth.ca\/news\/cadth-partners-international-health-technology-assessment-bodies-boost-collaboration-shared. Accessed 12 Oct 2023."},{"key":"606_CR16","unstructured":"Excellence TNIfHaC. NICE Partners with International Health Technology Assessment Bodies to Boost Collaboration on Shared Opportunities and Challenges. [https:\/\/www.nice.org.uk\/news\/article\/nice-partners-with-international-health-technology-assessment-bodies]. Accessed 12 Oct 2023."},{"key":"606_CR17","unstructured":"Excellence TNIfHaC. International Health Technology Assessment Collaboration Expands. https:\/\/www.nice.org.uk\/news\/article\/international-health-technology-assessment-collaboration-expands. Accessed 12 Oct 2023."},{"key":"606_CR18","unstructured":"De Abreu Louren\u00e7o R, Paige K, Haas M, Thomas T, Carrello J, Viney R, Goodall S. Consultation 1 Report. Australian Health Technology Assessment Methods and Policy Review. Canberra: Australian Government, Department of Health and Aged Care 2023;"},{"key":"606_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.healthpol.2016.08.006","volume":"120","author":"S Salas-Vega","year":"2016","unstructured":"Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy. 2016;120:1104\u201314.","journal-title":"Health Policy"},{"key":"606_CR20","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.3390\/curroncol29100602","volume":"29","author":"G Ball","year":"2022","unstructured":"Ball G, Levine MA, Thabane L, Tarride J-E. Appraisals by health technology assessment agencies of economic evaluations submitted as part of reimbursement dossiers for oncology treatments: evidence from Canada, the UK, and Australia. Curr Oncol. 2022;29:7624\u201336.","journal-title":"Curr Oncol"},{"key":"606_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10198-017-0871-0","volume":"19","author":"A Angelis","year":"2018","unstructured":"Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018;19:123\u201352. https:\/\/doi.org\/10.1007\/s10198-017-0871-0.","journal-title":"Eur J Health Econ"},{"key":"606_CR22","doi-asserted-by":"crossref","unstructured":"Turner AJ, Sammon C, Latimer N, Adamson B, Beal B, Subbiah V, Abrams KR, Ray J. Transporting comparative effectiveness evidence between countries: considerations for health technology assessments. Pharmacoeconomics. 2023:1\u201312.","DOI":"10.1007\/s40273-023-01323-1"},{"key":"606_CR23","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40273-013-0053-6","volume":"31","author":"F-L Zhao","year":"2013","unstructured":"Zhao F-L, Xie F, Hu H, Li S-C. Transferability of indirect cost of chronic disease: a systematic review and meta-analysis. Pharmacoeconomics. 2013;31:501\u20138.","journal-title":"Pharmacoeconomics"},{"key":"606_CR24","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.jval.2018.01.017","volume":"21","author":"S Wang","year":"2018","unstructured":"Wang S, Gum D, Merlin T. Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC\u2014does the presence of an explicit threshold affect the ICER proposed? Value Health. 2018;21:938\u201343.","journal-title":"Value Health"},{"key":"606_CR25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.healthpol.2018.08.019","volume":"123","author":"E Visintin","year":"2019","unstructured":"Visintin E, Tinelli M, Kanavos P. Value assessment of disease-modifying therapies for relapsing-remitting multiple sclerosis: HTA evidence from seven OECD countries. Health Policy. 2019;123:118\u201329. https:\/\/doi.org\/10.1016\/j.healthpol.2018.08.019.","journal-title":"Health Policy"},{"key":"606_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1169400","volume":"14","author":"L Gozzo","year":"2023","unstructured":"Gozzo L, Romano GL, Brancati S, Longo L, Vitale DC, Drago F. The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries. Front Pharmacol. 2023;14:1169400.","journal-title":"Front Pharmacol"},{"key":"606_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.vhri.2019.04.003","volume":"19","author":"A-P Holtorf","year":"2019","unstructured":"Holtorf A-P, Gialama F, Wijaya KE, Kal\u00f3 Z. External reference pricing for pharmaceuticals\u2014a survey and literature review to describe best practices for countries with expanding healthcare coverage. Value Health Reg Issues. 2019;19:122\u201331.","journal-title":"Value Health Reg Issues"},{"key":"606_CR28","unstructured":"Excellence TNIfHaC. A list of all our products on multiple sclerosis. https:\/\/www.nice.org.uk\/guidance\/conditions-and-diseases\/neurological-conditions\/multiple-sclerosis\/products?ProductType=Guidance&Status=Published. Accessed 10 Sep 2021."},{"key":"606_CR29","unstructured":"Health CAfDaTi. CDA. https:\/\/www.cda-amc.ca\/search?s=multiple%20sclerosis&op=OR&f%5B0%5D=project_line%3A108243. Accessed 10 Sep 2021."},{"key":"606_CR30","unstructured":"Consortium SM. SMC. https:\/\/www.scottishmedicines.org.uk\/search\/?keywords=multiple+sclerosis. Accessed 10 Sep 2021."},{"key":"606_CR31","unstructured":"Care AGDoHaA. Pharmaceutical Benefits Scheme (PBS). [https:\/\/www.pbs.gov.au\/pbs\/home. Accessed 10 Sept 2021."},{"key":"606_CR32","unstructured":"OECD. Exchange Rates (indicators). https:\/\/www.oecd.org\/en\/data\/indicators\/exchange-rates.html. Accessed 10 May 2021."},{"key":"606_CR33","unstructured":"OECD. Purchasing power parities (PPP) (indicator). https:\/\/data.oecd.org\/conversion\/purchasing-power-parities-ppp.htm. Accessed 10 May 2021."},{"issue":"7","key":"606_CR34","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s40273-018-0672-z","volume":"36","author":"AE Attema","year":"2018","unstructured":"Attema AE, Brouwer WBF, Claxton K. Discounting in economic evaluations. Pharmacoeconomics. 2018;36(7):745\u201358. https:\/\/doi.org\/10.1007\/s40273-018-0672-z.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"606_CR35","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11(6):e833\u201342.","journal-title":"Lancet Glob Health"},{"key":"606_CR36","unstructured":"P. H. A. o. Canada, Interpretation Guide\u2014Health Economics. https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/methods-process\/interpretation-guide-health-economics.html. Accessed 14 July 2024."},{"issue":"5","key":"606_CR37","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0178","volume":"13","author":"C Balijepalli","year":"2022","unstructured":"Balijepalli C, Gullapalli L, Joshy J, Rawson NS. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health. J Comp Eff Res. 2022;13(5):e230178.","journal-title":"J Comp Eff Res"},{"key":"606_CR38","unstructured":"C. A. f. D. a. T. i. Health. Single drug technology assessment processes across health technology assessment organizations, in Environmental scan, CADTH Ottawa; 2016."},{"key":"606_CR39","unstructured":"Allan Wailoo SD. The use of cost minimisation analysis for the appraisal of health technologies, University of Sheffield. https:\/\/sheffield.ac.uk\/nice-dsu\/methods-development\/cost-minimisation-analysis. Accessed 12 Oct 2023."},{"issue":"1","key":"606_CR40","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/hec.1812","volume":"22","author":"H Dakin","year":"2013","unstructured":"Dakin H, Wordsworth S. Cost-minimisation analysis versus cost-effectiveness analysis, revisited. Health Econ. 2013;22(1):22\u201334.","journal-title":"Health Econ"},{"issue":"2","key":"606_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","volume":"18","author":"SD Ramsey","year":"2015","unstructured":"Ramsey SD, et al. Cost-effectiveness analysis alongside clinical trials II\u2014an ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161\u201372.","journal-title":"Value Health"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00606-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:39:43Z","timestamp":1768473583000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00606-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00606-x","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication (from patients\/participants)"}},{"value":"All data used in this study were sourced from the official websites of HTA agencies, with corresponding website links cited in the references.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors have reviewed and agreed with the submission of manuscript. Author contributions: XW: Research design, data curation, formal analysis, methodology, writing\u2014original draft. FZ: Conceptualisation, data curation, methodology, writing\u2014review and edit. DN: Writing\u2014review and edit, supervision. LG: Writing\u2014review and edit. SL: Conceptualisation, research design, writing\u2014review and edit, supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}